18F-Fluciclovine (18F-FACBC) PET/CT or PET/MRI in gliomas/glioblastomas.
Domenico AlbanoDavide TomasiniMarco BonùRaffaele GiubbiniFrancesco BertagnaPublished in: Annals of nuclear medicine (2019)
18F-fluciclovine (18F-FACBC) is a radiotracer already studied for prostate cancer, and its potential role in brain tumors (such as glioma) is not yet well investigated despite promising results. The aim of this review is to evaluate the possible diagnostic role of 18F-FACBC PET/CT or PET/MRI in patients with gliomas and glioblastomas. A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase, and Cochrane library databases was conducted to find the relevant published articles about the diagnostic performance of FACBC PET/CT or PET/MRI in patients affected by glioma and/or glioblastoma. Seven papers were included in the systematic review. From the analyses of the selected studies, the following main findings were obtained: glioma and glioblastoma are FACBC-avid tumors with a detection rate of about 100%; FACBC PET has high-diagnostic accuracy in defining tumor extent, volumes, and satellite lesions better than MR; compared to methionine, FACBC has similar accuracy but better tumor-to-background contrast; FACBC uptake may help to discriminate between low-grade and high-grade glioma. Radiolabelled fluciclovine (18F-FACBC) imaging seems to be useful in analyzing glioma/glioblastoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of 18F-FACBC in this setting and its possible position in the diagnostic flowchart.
Keyphrases
- pet ct
- high grade
- low grade
- systematic review
- positron emission tomography
- contrast enhanced
- prostate cancer
- magnetic resonance imaging
- magnetic resonance
- end stage renal disease
- computed tomography
- newly diagnosed
- diffusion weighted imaging
- high resolution
- chronic kidney disease
- randomized controlled trial
- prognostic factors
- pet imaging
- ejection fraction
- artificial intelligence